Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1813731
Max Phase: Preclinical
Molecular Formula: C33H47F3N2O4S
Molecular Weight: 624.81
Molecule Type: Small molecule
Associated Items:
ID: ALA1813731
Max Phase: Preclinical
Molecular Formula: C33H47F3N2O4S
Molecular Weight: 624.81
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C[C@@H]1CN(S(=O)(=O)c2ccccc2C(F)(F)F)[C@@H](C)CN1C[C@@]1(O)CC[C@@]2(C)[C@@H](CC[C@@H]3[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]32)C1
Standard InChI: InChI=1S/C33H47F3N2O4S/c1-21-19-38(43(41,42)28-8-6-5-7-27(28)33(34,35)36)22(2)18-37(21)20-32(40)16-15-30(3)23(17-32)9-10-24-25-11-12-29(39)31(25,4)14-13-26(24)30/h5-8,21-26,40H,9-20H2,1-4H3/t21-,22+,23+,24+,25+,26+,30+,31+,32-/m1/s1
Standard InChI Key: IYHGEKFCMCXIEF-AIQQMPNKSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 624.81 | Molecular Weight (Monoisotopic): 624.3209 | AlogP: 6.13 | #Rotatable Bonds: 4 |
Polar Surface Area: 77.92 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 1 |
#RO5 Violations: 2 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: | CX Basic pKa: 7.37 | CX LogP: 6.10 | CX LogD: 5.82 |
Aromatic Rings: 1 | Heavy Atoms: 43 | QED Weighted: 0.44 | Np Likeness Score: 0.54 |
1. Maltais R, Fournier MA, Poirier D.. (2011) Development of 3-substituted-androsterone derivatives as potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3., 19 (15): [PMID:21741247] [10.1016/j.bmc.2011.06.003] |
2. Djigoué GB, Kenmogne LC, Roy J, Maltais R, Poirier D.. (2015) Design, chemical synthesis and biological evaluation of 3-spiromorpholinone/3-spirocarbamate androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3., 23 (17): [PMID:26277760] [10.1016/j.bmc.2015.07.049] |
3. Kenmogne LC, Maltais R, Poirier D.. (2016) Synthesis of a dansyl-labeled inhibitor of 17β-hydroxysteroid dehydrogenase type 3 for optical imaging., 26 (9): [PMID:27025340] [10.1016/j.bmcl.2016.03.069] |
4. Cortés-Benítez F, Roy J, Maltais R, Poirier D.. (2017) Impact of androstane A- and D-ring inversion on 17β-hydroxysteroid dehydrogenase type 3 inhibitory activity, androgenic effect and metabolic stability., 25 (7): [PMID:28254377] [10.1016/j.bmc.2017.02.008] |
Source(1):